Adenosine for fast heart rates - [Medication] - Quest Diagnostics Patient Health Library Adenosine for fast heart rates Examples Brand Name Chemical Name Adenocard, Adenoscan adenosine How It Works Adenosine reduces the normal flow of the electrical impulses through the atrioventricular (AV) node of the heart.Adenosine can be very effective at slowing or ending a rapid heart rate if the problem is caused by an abnormal...
Drug Approvals - A NDA 11-522/S-029 4/11/02 - - - Adderall XR Oral Capsule, Rx Shire Laboratories NDA 21-303/S1 5/22/02 5/29/02 5/23/02 - Adderall XR Oral Capsule, Rx Shire Laboratories NDA 21-303 10/11/01 2/12/02 2/12/02 2/12/02 - Adderall Indications:- ADHD (Attention Deficit Hyperactive Disorder) Adenoscan (Adenosine) Injection, Rx Fujisawa Healthcare, Inc
http://www.fda.gov/cder/orange/appendix_a.txt 3, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN ACETAMINOPHEN, ACETAMINOPHEN (OTC) ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC) ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, ACETAMINOPHEN ACETAMINOPHEN, BUTALBITAL AND CAFFEINE, ACETAMINOPHEN ACETAMINOPHEN,...
Medicines, Ethics and Practice page 2
http://www.fda.gov/cder/foi/appletter/2001/20059s7ltr.pdf page 1
Prescription and OTC Drug Product List 6/1998 Prescription and Over-the-Counter Drug Product List - 18th Edition Cumulative Supplement Number 6: June 1998 [ Prescription - OTC ] ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST - ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE CAPTOPRIL; HYDROCHLOROTHIAZIDE TABLET; ORAL TABLET; ORAL OXYCODONE AND ACETAMINOPHEN CAPOZIDE 25/15 - ADD - AA DURAMED 325MG;5MG N40272 001 - ADD - AB BRISTOL...
DDPA May 1995 DEPARTMENT OF HEALTH AND HUMAN SERVICES, PUBLIC HEALTH SERVICE NDA NUMBER TRADE NAME APPLICANT ACTIVE INGREDIENT(S) APPROVAL DATE (DOSAGE FORM) STRENGTH(S) (CLASSIFICATION) CLASSIFICATION(S) ***ORIGINAL AND SUPPLEMENTAL NDAs*** FOR NEW DRUG PRODUCTS 19-915 MONOPRIL BRISTOL MYERS SQUIBB FOSINOPRIL SODIUM 02-MAY-95 (TABLET) PRINCETON, NJ 10MG (SUPPL-009) 08543 20MG 40MG (NEW INDICATION...
DDPA April 1995 19-821 SORIATANE ROCHE ACITRETIN 03-APR-95 (CAPSULE) NUTLEY, NJ 10MG 07110 25MG (RETINOID) [TREATMENT OF SEVERE RECALCITRANT PSORIASIS] 20-325 PEPCID AC MERCK FAMOTIDINE 17-APR-95 (TABLET) WEST POINT, PA 10MG 19486 (HISTAMINE H2- RECEPTOR ANTAGONIST) [PREVENTION AND TREATMENT OF FOOD AND BEVERAGE INDUCED HEARTBURN, ACID INDIGESTION, AND SOUR STOMACH] (OTC) 20-059 ADENOSCAN ...
Drug Approvals for December 1997 Also provides for the addition of Haemophilus influenzae to the presently approved indication for secondary bacterial infections of acute bronchitis Application #: 020522 Efficacy Supplement#: 004 Type: SE1 to Original New Drug Application Approval Date: 17-DEC-97 Trade Name: NUTROPIN AQ Dosage Form: INJECTABLE Applicant: GENENTECH INC Active Ingredient(s): SOMATROPIN, BIOSYNTHETIC...
Cover 0520.qxd This week's UK PDJ reports the entry into force on May 1 st , of the SPC for Pfizer's (formerly Pharmacia's) ibutilide.
author: GWhite
Cover 0520.qxd page 1
author: GWhite
Gazette Weekly Highlights News - Thomson Scientific Thomson.com - - - - - Advanced Search - - - EN : JP : CN : KR -- - - - Current Patents Gazette - Weekly Highlights News The gazette weekly highlights focuses on patent-related issues making the headlines, on noteworthy new applications, and on litigation and legislation affecting the industry.
BIOTECanada - Member News Welcome to the new Member News Archives.
1999 Warning Letters and Untitled Letters to Pharmaceutical Companies Food and Drug Administration • Center for Drug Evaluation and Research Compliance Activities Search Warning Letters and Untitled Letters to Pharmaceutical Companies 1999 These letters, sorted by month, are supplied by the CDER Freedom of Electronic Information Office
Reference Listed Drug Labeling Approved in August 2001 < td WIDTH="7%" VALIGN="middle" HEIGHT="18" style="font-family: MS Sans Serif; font-size: 8; border-bottom: 1px solid rgb(45,50,108)"> 20-450 S-005 CEREZYME letter - imiglucerase for injection 20-367 S-049 Aug 15 ACIPHEX letter label rabeprazole sodium delayed-release tablets 20-973 S-008 ULTRAM letter label tramadol HCl tablets 20-281 S-029 Aug 16 QUINIDEX letter label quinidine su...
author: USERNAME
http://www.fujisawa.co.jp/ir/ar2003/2003p2.pdf Millions of yen 2003 2002 2001 2000 1999 Results for the year: Net sales ¥ 382,079 ¥341,356 ¥297,517 ¥289,142 ¥277,281 Research and development expenses ...........Adenoscan ® (adenosine injection), and Protopic® ...
http://www.fujisawa.co.jp/ir/ar2003/2003p2.pdf page 5
http://www.fujisawa.co.jp/ir/ar2003/2003p2.pdf page 4
http://www.fujisawa.co.jp/ir/ar2003/2003p2.pdf page 2
Fujisawa Pharmaceutical Co., Ltd. Fujisawa Healthcare, Inc
Fujisawa Pharmaceutical Co., Ltd. Fujisawa's core business is its line of ethical pharmaceutical products, accounting for approximately 90 % of net sales
http://www.fujisawa.co.jp/ir/ar2003/2003h_1.pdf ANNUAL REPORT 2003 1 Fujisawa Pharmaceutical Co., Ltd., headquartered in Japan, is a research- driven pharmaceutical company with a firm commitment to innovative research in its quest to satisfy unmet medical needs and contribute to the progress of medical careAdenoscan ® (adenosine injection)...
http://www.fujisawa.co.jp/english/ir/pdf/ar2000/data/f_2000p2.pdf 17 Fujisawa Pharmaceutical Company Limited and Consolidated Subsidiaries Selected Financial Data Years Ended March 31 Millions of yen 2000 1999 1998 1997 1996 Results for the year: Net sales ¥289,142 ¥277,281 ¥281,584 ¥282,945 ¥265,897 Research and development expenses ........Adenoscan grew, and sales...
http://www.fujisawa.co.jp/english/ir/pdf/ar2000/data/f_2000p2.pdf page 2
http://www.fujisawa.co.jp/english/ir/pdf/ar2002/data/f_2002p2.pdf Millions of yen 2002 2001 2000 1999 1998 Results for the year: Net sales ¥341,356 ¥297,517 ¥289,142 ¥277,281 ¥281,584 Research and development expenses ........Adenoscan ® , AmBisome ® , and the newly launched Protopic ®
